Low-Level Light Therapy for Hair Regrowth - Quick Reference Sheet
evipedia.ai ← Back

Low-Level Light Therapy for Hair Regrowth

Created on 08/09/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A wearable at-home cap or comb that shines red light on the scalp. Pooled studies show it adds hair in pattern hair loss in men and women, and more alongside topical minoxidil. The gain is real but modest and takes four to six months of every-other-day use. Safety is the clearest strength; nearly every trial was funded by device makers. (Full Review)

Protocol

Dose per session
3–90 mW/cm² for 10–25 min
Approximately 1–10 J/cm²; not extended beyond the labelled duration
Frequency
3 sessions per week
On alternate days; lower frequency outperformed higher frequency
Wavelength selection
650–660 nm
Some add 630–680 nm diode output or near-infrared at 808–850 nm
Time to effect
Decision point
26 weeks
Effect grows through 26 weeks and beyond; larger pooled effect beyond 20 weeks
First measurable change
16 weeks
Minimum before assessment; 8 or 12 weeks produces a false negative
Nothing measurable
Before 12 weeks
A hair-cycle constraint, not a device limitation

Benefits

Contraindications
  • Undiagnosed pigmented, ulcerated, or changing scalp lesion, or history of scalp melanoma or squamous cell carcinoma in the field, until dermatological assessment
  • Active photosensitivity disorder (porphyria cutanea tarda, erythropoietic protoporphyria, xeroderma pigmentosum, solar urticaria, lupus with photosensitive rash)
  • Within 48 hours of topical photodynamic therapy (aminolevulinic acid, methyl aminolevulinate) to scalp or forehead
  • Photosensitive epilepsy (pulsed or flickering emission modes)
  • Pregnant and breastfeeding women
  • Scarring alopecia in the treated field; Norwood-Hamilton VI–VII slick-bald scalp
  • Children and adolescents under 18
    •
Key Interactions
  • Photosensitizing prescription drugs (doxycycline, ciprofloxacin, amiodarone, hydrochlorothiazide, isotretinoin, methotrexate, psoralens)
  • Photosensitizing and irritant topicals (piroxicam gel, topical retinoids, glycolic exfoliants, coal tar shampoos, benzoyl peroxide)
  • St. John's wort (Hypericum perforatum)
  • High-dose antioxidants (vitamin C above 1,000 mg, vitamin E above 400 IU, N-acetylcysteine above 1,200 mg daily)
  • Other interventions (microneedling, platelet-rich plasma, transplantation, micropigmentation)
  • Topical minoxidil (beneficial additive)
  • 5-alpha-reductase inhibitors (finasteride, dutasteride)
  • Supplements with additive hair effects (topical melatonin, saw palmetto, topical caffeine, rosemary oil, procyanidin B2, biotin)
  • Ketoconazole shampoo
    •

Risk & Side Effects

  • High: Mild, transient scalp symptoms
    •
  • Medium: Ocular hazard from direct laser exposure
    •
  • Low: Temporary increased shedding early in treatment; photosensitivity reactions; scalp erythema and heat discomfort from high-irradiance or poorly ventilated devices; paradoxical hypertrichosis at treatment margins
  • Speculative: Stimulation of pre-existing scalp neoplasia; loss of benefit from cumulative overdosing

Monitoring

Marker Target Why
Ferritin 70–100 ng/mL (women); 100–150 ng/mL (men) Iron stores limit follicle matrix cell division
25-hydroxyvitamin D 40–60 ng/mL Required for normal follicle cycling
TSH 1.0–2.0 mIU/L Thyroid dysfunction causes shedding that mimics device failure
Free testosterone Mid-to-upper reference range for age and sex The androgenic driver light therapy does not address
DHT Within reference range; interpreted against testosterone The androgen directly responsible for follicle miniaturisation
Serum zinc 90–120 µg/dL Cofactor for follicle protein synthesis
Hemoglobin and complete blood count Hemoglobin 13.5–15.0 g/dL (women); 14.5–16.0 g/dL (men) Detects anaemia and systemic illness that suppress hair cycling
hs-CRP Below 1.0 mg/L Systemic inflammation suppresses follicle cycling

Cadence: Standardised photographs and a baseline laboratory panel before starting; adherence check at 8 weeks with no measurement attempted; first photographic and count reassessment at 16 weeks; decision point at 26 weeks; every 6 months thereafter. Abnormal baseline values are rechecked 12 weeks after correction; normal values every 12 months.

Qualitative Assessment

  • Shedding volume — hairs lost in the shower and on the pillow, counted for three days at baseline and at 16 weeks
  • Scalp visibility in bright overhead light — sensitive to shaft diameter rather than hair count
  • Hair texture and manageability — whether hair holds a style and feels thicker at the root
  • Adherence rate — sessions completed as a percentage of sessions scheduled
  • Tolerability — tingling, warmth, or dryness persisting beyond an hour after a session
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.